Forecast & Rating7 analysts currently cover KalVista Pharma, with about 14.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.60, about 5.9% upside from the current price of $27.00. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 3.4% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on KalVista Pharma's outlook. Data as of Jun 11, 2026; for reference only and not investment advice.
May 15, 2026Price forecast
$28.605.93%
Forecast & RatingHold
7analysts
- Strong buy14.29%
- Buy0.00%
- Hold85.71%
- Sell0.00%
- Strong sell0.00%
Target price forecast
Forecast dateJun 7, 2026
Forecast met8.1%
Stock price$27.00
Avg. target$28.6
High target$35
Low target$27
Analyst ratings
Strong buy
Buy
Hold
Sell
Strong sell
Source: S&P Global
This information is for reference only and is not investment advice.